2011
DOI: 10.1016/j.taap.2011.03.013
|View full text |Cite
|
Sign up to set email alerts
|

Beneficial effects of carbon monoxide-releasing molecule-2 (CORM-2) on acute doxorubicin cardiotoxicity in mice: Role of oxidative stress and apoptosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
46
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 64 publications
(52 citation statements)
references
References 51 publications
6
46
0
Order By: Relevance
“…Furthermore, to draw firm mechanistic conclusions it will be necessary to use a genetic manipulation approach. In addition, although the induction of mitochondrial biogenesis through the administration of CO, CO-releasing molecules, or metformin treatment seemed to be helpful in acute and subacute anthracycline cardiotoxicity settings (Piantadosi and Suliman, 2006;Asensio-López et al, 2011;Soni et al, 2011;Ashour et al, 2012), it will be important to reveal whether this intervention may have a therapeutic value against chronic anthracycline cardiotoxicity.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, to draw firm mechanistic conclusions it will be necessary to use a genetic manipulation approach. In addition, although the induction of mitochondrial biogenesis through the administration of CO, CO-releasing molecules, or metformin treatment seemed to be helpful in acute and subacute anthracycline cardiotoxicity settings (Piantadosi and Suliman, 2006;Asensio-López et al, 2011;Soni et al, 2011;Ashour et al, 2012), it will be important to reveal whether this intervention may have a therapeutic value against chronic anthracycline cardiotoxicity.…”
Section: Discussionmentioning
confidence: 99%
“…CORM-2 dosing was based on past dose titration studies and reported effectiveness of a single systemic 8-mg/kg dose in rodents (44)(45)(46). CORM-2 (8 mg/kg i.v.…”
Section: Methodsmentioning
confidence: 99%
“…Doxorubicin is a chemotherapeutic drug widely used in many combined regimens for NHL. However, fatal cardiotoxicity has been a major limitation (Soni et al, 2011). Strategies to decrease doxorubicin toxicity by minimizing doxorubicin effects in chemotherapeutic doses and improving its efficacy are urgently needed to better treat cancer patients.…”
Section: Introductionmentioning
confidence: 99%